Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer. Fang Q, You C, Xiao X, Yang W, et al. Int J Biol Macromol 2026;343.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fang Q, You C, Xiao X, Yang W, et al. Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer. Int J Biol Macromol 2026;343.
PMID: 41581813